MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer?

被引：4
|
作者：
Renaud, Stephane [1 ]
Seitlinger, Joseph [2 ]
Massard, Gilbert [2 ]
机构：
[1] Nancy Univ Hosp, Inst Lorrain Coeur & Vaisseaux Louis Mathieu, Dept Thorac Surg, Nancy, France
[2] Strasbourg Univ Hosp, Dept Thorac Surg, Strasbourg, France
来源：
JOURNAL OF THORACIC DISEASE | 2017年 / 9卷 / 04期
关键词：
K-RAS MUTATIONS; PROGNOSTIC VALUE; EGFR MUTATIONS; ADENOCARCINOMA; SUBSTITUTIONS; METASTASIS; BEHAVIOR; MIR-29B; IMPACT; GROWTH;
D O I：
10.21037/jtd.2017.03.56
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：957 / 960
页数：4
相关论文
共 50 条
  • [31] MicroRNAs EXPRESSION PROFILES IN NON-SMALL CELL LUNG CANCER
    Yaroglu, Hatice Yildirim
    Akbayir, Serin
    Gorur, Aysegul
    Balci, Senay
    Unal, Nil
    Ayaz, Lokman
    Ayan, Erhan
    Tamer, Lulufer
    FRESENIUS ENVIRONMENTAL BULLETIN, 2021, 30 (7A): : 9107 - 9113
  • [32] Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer
    Gong, Feng-Yun
    Bai, Tao
    Zhang, Ding-Yu
    Huang, Chao-lin
    Lv, Jing
    Wang, Jing-Li
    Hu, Xu-Dong
    Wang, Juan
    Liu, Wei
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 5973 - 5982
  • [33] Contribution of smoking habit to the prognosis of stage I KRAS-mutated non-small cell lung cancer
    Kuroda, Hiroaki
    Yoshida, Tatsuya
    Arimura, Takaaki
    Mizuno, Tetsuya
    Sakakura, Noriaki
    Yatabe, Yasushi
    Sakao, Yukinori
    CANCER BIOMARKERS, 2018, 23 (03) : 419 - 426
  • [34] Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Peravali, M.
    Gomes-Lima, C.
    Tefera, E.
    Baker, M.
    Sherchan, M.
    Farid, S.
    Burman, K.
    Constantinescu, F.
    Veytsman, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S300 - S301
  • [35] The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
    Torralvo, Javier
    Friedlaender, Alex
    Achard, Verane
    Addeo, Alfredo
    CANCER GENOMICS & PROTEOMICS, 2019, 16 (06) : 577 - 582
  • [36] Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
    Matikas, Alexios
    Mistriotis, Dimitrios
    Georgoulias, Vasilios
    Kotsakis, Athanasios
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 110 : 1 - 12
  • [37] KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
    Liguori, Luigi
    Salomone, Fabio
    Viggiano, Angela
    Sabbatino, Francesco
    Pepe, Stefano
    Formisano, Luigi
    Bianco, Roberto
    Servetto, Alberto
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 205
  • [38] Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
    Rosner, S.
    Zaidi, N.
    Wang, H.
    Smith, K.
    Nauroth, J.
    Guo, M.
    Fitzpatrick, P.
    Riemer, J.
    Barnes, A.
    Wenga, P.
    Feliciano, J.
    Hann, C.
    Lam, V.
    Murray, J.
    Scott, S.
    Anagnostou, V.
    Levy, B.
    Forde, P.
    Brahmer, J.
    Jaffee, E.
    Marrone, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S382 - S383
  • [39] Resistance to KRAS inhibition in advanced non-small cell lung cancer
    Sreter, Katherina Bernadette
    Catarata, Maria Joana
    von Laffert, Maximilian
    Frille, Armin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer
    Havva O Kilgoz
    Guzide Bender
    Joseph M Scandura
    Agnes Viale
    Bahar Taneri
    Molecular Medicine, 2016, 22 : 380 - 387
12345